Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02307552).
- Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]: Complete Statistical AnalysisIndependent statistical analysis of Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]: primary endpoint results, effect estimate with confidence interval, sample-size…
- Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Treat & TrainIndependent statistical analysis of A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA): primary endpoint results, effect estimate with…
- Treat COVID-19 Patients With Regadenoson: Complete Statistical AnalysisIndependent statistical analysis of Treat COVID-19 Patients With Regadenoson: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04606069).
- Treating COVID-19 With Hydroxychloroquine (TEACH): Complete Statistical AnalysisIndependent statistical analysis of Treating COVID-19 With Hydroxychloroquine (TEACH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04369742).
- Treating H. Pylori in Parkinson’s Patients With Motor Fluctuations: Complete Statistical AnalysisIndependent statistical analysis of Treating H. Pylori in Parkinson's Patients With Motor Fluctuations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00664209).
- Treating Low-Income Smokers in the Hospital Emergency Department: Complete Statistical AnalysisIndependent statistical analysis of Treating Low-Income Smokers in the Hospital Emergency Department: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01328431).
- Treating Nonalcoholic Steatohepatitis With Pioglitazone: Complete Statistical AnalysisIndependent statistical analysis of Treating Nonalcoholic Steatohepatitis With Pioglitazone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00062764).
- Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TremelimumabIndependent statistical analysis of Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TRFIndependent statistical analysis of Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- trinkfitIndependent statistical analysis of Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TRITON3Independent statistical analysis of A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency: primary endpoint results, effect estimate with confidence…
- TROYAIndependent statistical analysis of Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment: primary endpoint results, effect…
- TRUSTIndependent statistical analysis of Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02917265).
- TTRACKIndependent statistical analysis of Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TULIP-LN1Independent statistical analysis of Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis: primary endpoint results, effect estimate with confidence interval, sample-size…
- TURFIndependent statistical analysis of Study for Recalcitrant Age Related Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01543568).
- TURQUOISE-CPBIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4…
- TVEC-325Independent statistical analysis of Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TWO2DFUIndependent statistical analysis of Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- TWPSIndependent statistical analysis of Long-Term Effects of Torso-Weighting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02743312).
- TX-SMILEIndependent statistical analysis of Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03682965).
- Tx-TreatmentIndependent statistical analysis of Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- UCDCC#217Independent statistical analysis of Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- UGIH09067Independent statistical analysis of Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ULT-218Independent statistical analysis of Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03320096).
- UNCOVER-3Independent statistical analysis of A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01646177).
- UNIFIIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis: primary endpoint results, effect estimate…
- Unite-CNMIndependent statistical analysis of Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- UNIVERSEIndependent statistical analysis of Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure: primary endpoint results, effect estimate…
- upreACH-2Independent statistical analysis of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- URIDxEDIndependent statistical analysis of Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02957136).
- urochesterIndependent statistical analysis of Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- UVIndependent statistical analysis of Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- VA CARDSIndependent statistical analysis of Coronary Artery Revascularization in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326196).
- VECTORIndependent statistical analysis of Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VEGAIndependent statistical analysis of Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396316).
- VELVETIndependent statistical analysis of A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor…
- VERITASIndependent statistical analysis of A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal…
- VERITASIndependent statistical analysis of Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary: primary endpoint…
- VERONICAIndependent statistical analysis of the VERONICA phase 2 trial comparing venetoclax plus fulvestrant with fulvestrant in women with ER-positive, HER2-negative locally advanced or metastatic breast cancer after CDK4/6 inhibitor therapy.
- VIBRANTIndependent statistical analysis of Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO): primary endpoint results, effect estimate with confidence…
- VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…
- VICTORY-AFIndependent statistical analysis of Evaluation of the Phased Radio Frequency Ablation System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01693120).
- VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.
- VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…